← All trials
NCT04279613
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2020
- Primary completion
- Dec 26, 2021
- Completion date
- Dec 26, 2022
- First posted
- Feb 21, 2020
- Last posted
- Feb 21, 2020
- Enrollment
- 48
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Lead sponsor
- Novo NordiskCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.